EpCAM and COX-2 expression are positively correlated in human breast cancer

Gao, Shuhang; Sun, Yunyan; Li, Xue; Zhang, Dandan; Yang, Xuesong

doi:10.3892/mmr.2017.6447

Cited by 18 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is increasing evidence that cancer stem cells in tumor tissues may contribute to recurrence in many cancers. Reports have shown that the CSC marker, EpCAM, may be successfully used as a tumor marker in gastric, ovarian, and breast cancer because its high expression in these cancers is closely related to tumor growth, metastasis and advanced tumor stage (30)(31)(32). Similarly, increased expression of LGR5 in esophageal cancer and neuroblastoma can enhance tumor cell invasion and migration (33,34).…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway

Wang

Lin

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Thyroid cancer is one of the most common malignant tumors of the endocrine system. Among all thyroid cancers, papillary thyroid carcinoma (PTC) is the most common type. The BRAF-activated non-coding RNA (BANCR) is a 693-bp nucleotide transcript which was first identified in melanoma. However, the role of BANCR in the development of thyroid cancer remains unclear. Therefore, the present study investigated the potential involvement of BANCR in the development of thyroid cancer in vitro using patient tissue samples and a panel of thyroid cancer cell lines, and in vivo using a xenograft mouse model. We observed that BANCR was expressed at a higher level in human thyroid tumor tissues than that noted in the adjacent normal tissues. The expression level of BANCR differed between cultured thyroid cancer cell lines; BANCR expression was lower in the BCPAP cell line than that observed in the CAL-62, WRO and FTC-133 cell lines. Western blot analysis and flow cytometry revealed that overexpression of BANCR in the BCPAP cell line resulted in increased expression of the cancer stem cell markers, LGR5 and EpCAM. Single-clone formation experiments showed that upregulated expression of BANCR in the BCPAP cell line promoted an increase in the number of clones formed. Similarly, in microsphere formation experiments, overexpression of BANCR resulted in increased number and size of microspheres compared with the control cell line. Western blotting experiments showed that BANCR overexpression in BCPAP upregulated the expression of phosphorylated c-Raf, MEK1/2 and ERK1/2. Inhibition of c-Raf via U0126 decreased the expression of LGR5 and EpCAM, as well as phosphorylated levels of c-Raf, MEK1/2 and ERK1/2 in the BCPAP cells, compared to levels in the DMSO controls. In the xenograft mouse model, BANCR overexpression in the thyroid cancer cells significantly increased tumor growth. Taken together, these results suggest that BANCR plays a role in PTC development by regulating the expression of cancer stem cell markers LGR5 and EpCAM via the c-Raf/MEK/ERK signaling pathway. Therefore, BANCR may be used as a novel prognostic marker for PTC.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway

Wang

Lin

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Among these proteins related to ZG16B, LYZ [66] and PRR4 [67] have protective function in tears and various body fluids, which are corresponding to Perumal's research [45,46]. S100PBP [68], PRR4 [69], ANKEF1 [39,70], EPCAM [71], SPDEF [72], KRT8, KRT19 [73], KIAA1324 [74,75], CXCR4 [76,77], AGR2 [78][79][80], SCNN1A [81], AP1M2 [82], CLDN4 [83], and ERBB3 [84,85] have been reported to have correlations with breast cancer or have been identified as biomarkers for diagnosis, metastasis, and prognosis of breast cancer and even as therapeutic targets. Interestingly, FAM96B is reported to inhibit VEGF receptor 2 promoter to restrain endothelium activity through the control of E2-2 expression [86].…”

Section: Discussionmentioning

confidence: 99%

Identification of ZG16B as a prognostic biomarker in breast cancer

et al. 2020

View full text Add to dashboard Cite

Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn’t been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan–Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.

show abstract

“…In recent decades, COX2 has been reported to be overexpressed in a variety of human tumors, including breast, lung, colon, skin, bone, cervical, esophageal, pancreatic, prostate, and bladder cancer 1,[12][13][14][15][16][17][18][19] .…”

Section: Discussionmentioning

confidence: 99%

Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway

et al. 2019

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of death among gynecological malignancies. Cyclooxygenase 2 is widely expressed in various cancer cells and participates in the occurrence and development of tumors by regulating a variety of downstream signaling pathways. However, the function and molecular mechanisms of cyclooxygenase 2 remain unclear in ovarian cancer. Here, we demonstrated that cyclooxygenase 2 was highly expressed in ovarian cancer and the expression level was highly correlated with ovarian tumor grades. Further, ovarian cancer cells with high expression of cyclooxygenase 2 exhibit enhanced proliferation and invasion abilities. Specifically, cyclooxygenase 2 promoted the release of prostaglandin E2 upregulated the phosphorylation levels of phospho-nuclear factor-kappa B p65. Celecoxib, AH6809, and BAY11-7082 all can inhibit the promoting effect of cyclooxygenase 2 on SKOV3 and OVCAR3 cell proliferation and invasion. Besides, celecoxib inhibited SKOV3 cell growth in the xenograft tumor model. These data suggest that high expression of cyclooxygenase 2 promotes the proliferation and invasion of ovarian cancer cells through the prostaglandin E2/nuclear factor-kappa B signaling pathway. Cyclooxygenase 2 may be a potential therapeutic target for the treatment of ovarian cancer.

show abstract

EpCAM and COX-2 expression are positively correlated in human breast cancer

Cited by 18 publications

References 25 publications

Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway

Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway

Identification of ZG16B as a prognostic biomarker in breast cancer

Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway

Contact Info

Product

Resources

About